Drovelis® – the new choice for contraception.

This paper summarizes the significant information provided by literature on the advantages of a new combined oral contraceptive (COC) – Drovelis®. Drovelis® is an innovative oral contraceptive composed of estetrol (E4), a native estrogen produced exclusively by the human fetal liver during pregnancy, which in clinical use is synthesized from a plant source, and drospirenone (DRSP), a progestin that has been in composition of other hormonal contraceptives. E4 15 mg/ DRSP 3 mg results in the adequate inhibition of ovulation and suppression of ovarian function comparable to a combined oral contraceptive containing EE/DRSP. The 15 mg E4/3 mg DRSP combination has been shown to provide the most favorable bleeding pattern and menstrual cycle control. Drovelis® is associated with a high user acceptability and satisfaction and with a favorable body weight control. In conclusion, E4/DRSP is an effective and generally well-tolerated COC that expands the number of available options for contraception with a potentially low risk of thrombotic events. [ABSTRACT FROM AUTHOR]